ArchiveFebruary 2012

McMahon J, McQuaid S, Reynolds R, Fitzgerald U. Increased expression of ER stress- and hypoxia-associated molecules in grey matter lesions in multiple sclerosis. Mult Scler. 2012 Feb 21. [Epub ahead of print] Background: The endoplasmic reticulum (ER) stress pathway may play a role in the pathogenesis multiple sclerosis (MS), and while ER stress-associated molecules have been demonstrated in...

Locatelli et al. Primary oligodendrocyte death does not elicit anti-CNS immunity. Nature Neuroscience (2012) doi:10.1038/nn.3062 [Epub ahead of print] Anti-myelin immunity is commonly thought to drive multiple sclerosis, yet the initial trigger of this autoreactivity remains elusive. One of the proposed factors for initiating this disease is the primary death of oligodendrocytes. To specifically...

This week we say Auf Wiedersehen to our Prima German Student …Caren, who is a regular blog reader.
Caren and Jo being wicked at Halloween selling cakes for a good cause
Congrats to Team G and the EyeDoctor for raising another wad of cash for MS charity at the Valentine’s Day Bake a couple of Weeks Ago.
P.S. The MouseDoc’s CarrotCake sold like hot cakes!

Polman CH et al. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. Anal Neurol 68:292-302 New evidence and consensus has led to further revision of the McDonald Criteria for diagnosis of multiple sclerosis. The use of imaging for demonstration of dissemination of central nervous system lesions in space and time has been simplified, and in some circumstances...

Epub ahead of print: Sinnecker et al. Multiple Sclerosis Lesions and Irreversible Brain Tissue Damage: A Comparative Ultrahigh-Field Strength Magnetic Resonance Imaging Study. Arch Neurol. 2012 Feb 20. BACKGROUND: In current clinical practice, T2-weighted magnetic resonance imaging (MRI) is commonly applied to quantify the accumulated multiple sclerosis (MS) lesion load, whereas T1-weighted...

Next vid up is Dr Klaus Schmierer’s talk on his latest research:
White matter? Grey matter? The whole brain matters!

Leave your comments and questions for Dr Klaus on the Shift.ms website.

Rio et al. Change in the clinical activity of multiple sclerosis after treatment switch for suboptimal response. Eur J Neurol. 2012 Jan 31Background: Therapy for multiple sclerosis (MS) has a partial efficacy, and a significant proportion of treated patients will develop a suboptimal response with first line disease-modifying drugs (DMD). Therapy switch in patients with MS can be a strategy after...

Sometimes You want to post a comment that is Unrelated to the thread.
Therefore I have Created this Spot for You It jumps around so that it is visible

I have been collecting CCSVI papers up to post every now and again post, rather than posting them as they appear. As every, we report without comments. Digest as you will, our take will change if evidence dictates that we change our view. It is interesting that the UK MS Society has got fed up dealing with a monoculture of facebook posts on this subject to the detriment of everything else…...

Dr Ben Turner talks about new therapies

If you can not see the video please come to the website.

Produced by Shift.ms for Team G. This what your are missing if you do not follow the links